Market revenue in 2021 | USD 1,032.2 million |
Market revenue in 2030 | USD 2,317.7 million |
Growth rate | 9.4% (CAGR from 2021 to 2030) |
Largest segment | Anthrax |
Fastest growing segment | Radiation/nuclear |
Historical data covered | 2018 - 2020 |
Base year for estimation | 2021 |
Forecast period covered | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Anthrax, Small Pox, Botulism, Radiation/nuclear |
Key market players worldwide | Altimmune Inc, Emergent BioSolutions Inc, Dynavax Technologies, SIGA Technologies Inc, Elusys Therapeutics, Ichor Medical Systems, Cleveland-Cliffs Inc, Bavarian Nordic A/S, Ology Bioservices, Alnylam Pharmaceuticals Inc, XOMA |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biodefense market will help companies and investors design strategic landscapes.
Anthrax was the largest segment with a revenue share of 29.04% in 2021. Horizon Databook has segmented the Europe biodefense market based on anthrax, small pox, botulism, radiation/nuclear covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe biodefense market , including forecasts for subscribers. This continent databook contains high-level insights into Europe biodefense market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account